MX2023010997A - Métodos de administración de polipéptidos de la hormona del crecimiento de acción prolongada. - Google Patents

Métodos de administración de polipéptidos de la hormona del crecimiento de acción prolongada.

Info

Publication number
MX2023010997A
MX2023010997A MX2023010997A MX2023010997A MX2023010997A MX 2023010997 A MX2023010997 A MX 2023010997A MX 2023010997 A MX2023010997 A MX 2023010997A MX 2023010997 A MX2023010997 A MX 2023010997A MX 2023010997 A MX2023010997 A MX 2023010997A
Authority
MX
Mexico
Prior art keywords
growth hormone
methods
long
acting growth
hormone polypeptides
Prior art date
Application number
MX2023010997A
Other languages
English (en)
Spanish (es)
Inventor
Jóse Francisco Cara
Aleksandra Pastrak
Srinivas Rao Valluri
Michael Paul Wajnrajch
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2023010997A publication Critical patent/MX2023010997A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2023010997A 2021-03-19 2022-03-17 Métodos de administración de polipéptidos de la hormona del crecimiento de acción prolongada. MX2023010997A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163163504P 2021-03-19 2021-03-19
US202163272417P 2021-10-27 2021-10-27
PCT/US2022/020804 WO2022197961A1 (en) 2021-03-19 2022-03-17 Methods of administering long-acting growth hormone polypeptides

Publications (1)

Publication Number Publication Date
MX2023010997A true MX2023010997A (es) 2023-11-28

Family

ID=83320806

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010997A MX2023010997A (es) 2021-03-19 2022-03-17 Métodos de administración de polipéptidos de la hormona del crecimiento de acción prolongada.

Country Status (10)

Country Link
US (1) US20240166710A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308151A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022145646A (cg-RX-API-DMAC7.html)
KR (1) KR20230171936A (cg-RX-API-DMAC7.html)
AU (1) AU2022238386A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023018980A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214273A1 (cg-RX-API-DMAC7.html)
IL (1) IL305661A (cg-RX-API-DMAC7.html)
MX (1) MX2023010997A (cg-RX-API-DMAC7.html)
WO (1) WO2022197961A1 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155990A1 (en) * 2001-04-20 2002-10-24 Renasci, Inc., D/B/A Renasci Anti-Aging Center Method of optimizing growth hormone replacement
WO2009102734A1 (en) * 2008-02-11 2009-08-20 Depomed Inc. Methods for treating vasomotor symptoms using gaba analogs in a gastric retentive dosage form
US20150158926A1 (en) * 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
HUE050002T2 (hu) * 2013-10-21 2020-11-30 Opko Biologics Ltd Hosszan ható polipeptidek és eljárás azok elõállítására és beadására
EP4732848A3 (en) * 2014-11-21 2026-07-29 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
KR102527180B1 (ko) * 2014-12-10 2023-04-27 옵코 바이오로직스 리미티드 장기간 작용성 ctp-변형된 성장 호르몬 폴리펩타이드의 제조 방법
MY184625A (en) * 2014-12-10 2021-04-09 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides

Also Published As

Publication number Publication date
BR112023018980A2 (pt) 2023-12-05
EP4308151A4 (en) 2025-02-26
EP4308151A1 (en) 2024-01-24
WO2022197961A1 (en) 2022-09-22
CA3214273A1 (en) 2022-09-22
KR20230171936A (ko) 2023-12-21
US20240166710A1 (en) 2024-05-23
JP2022145646A (ja) 2022-10-04
AU2022238386A1 (en) 2023-09-14
IL305661A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
MX2024000049A (es) Degradador de tirosina cinasa y mutante de bruton, composicion y aplicacion del mismo.
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
MX2019005466A (es) Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia.
de Almeida et al. A hypothesis for the anti-inflammatory and mechanotransduction molecular mechanisms underlying acupuncture tendon healing
NZ610487A (en) Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
JOP20190019B1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
MX2025011882A (es) Metodos de tratamiento del cancer con un agonista del receptor de linfotoxina beta
MX2019003751A (es) Proteina terapeutica.
MX2022009712A (es) Tratamiento de infeccion por coronavirus con interferon lambda.
MX2025009578A (es) Regimenes y composiciones utiles para aliviar el dolor
MX2023003258A (es) Tratamiento de enfermedades mediadas por nf-kb.
MX2023006704A (es) Composiciones dsg2 y metodos para el tratamiento de covid-19.
MX2025006619A (es) Compuestos terapeuticos
UA81689C2 (ru) Способ предоперационного лечения послеоперационной боли бупренорфином
AU2014284101B2 (en) Treating skin ulcers
RU2018132694A (ru) Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста
BR112023018980A2 (pt) Métodos de administração de polipeptídeos de hormônio de crescimento de ação prolongada
Anwar et al. Combined botulinum toxin injections and phenol nerve/motor point blocks to manage multifocal spasticity in adults
BRPI0508982A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
MX2024005327A (es) Composiciones y metodos de dsg2.
ZA202201446B (en) Methods of treating multifocal cancer
MX2024005084A (es) Tratamientos administrados de manera subcutanea para enfermedad de parkinson avanzada.
Kim et al. The Effect of Functional Electrical Stimulation on Hemiplegic Shoulder Subluxation.
WO2022240804A3 (en) Methods of treating sickle cell disorder and related conditions